MLH1 and neoplasm: The loss of MLH1/PMS2 expression, compared to pMMR, was associated with shorter disease-free survival in patients with lymphovascular invasion (p < 0.05), perineural invasion (p < 0.01), stage III (p < 0.05), and high-grade tumor (p < 0.05)—Figure 2.